ArticleBritish journal of pharmacology1995
The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors.
Article in British journal of pharmacology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed.
- Acute S-ketamine application does not alter cerebral [18F]altanserin binding: a pilot PET study in humans.Journal of neural transmission (Vienna, Austria : 1996) · 2007Trial
- Serotonin inhibits the influx of iron into cells by decreasing the expression of SLC11A2 in Caco-2 cells.Biomedical reports · 2026Article
- Distinctive patterns of G protein coupling induced by the structurally similar 5-HTMolecular pharmacology · 2025Article
- Discovery of a Novel, Potent, and Selective 5‑Hydroxytryptamine 2B Receptor Antagonist that Induces Mitochondrial Biogenesis in the Kidney.ACS pharmacology & translational science · 2025Article
- Artificial intelligence approaches for anti-addiction drug discovery.Digital discovery · 2025Review
- Article
- Targeting 5-HT Is a Potential Therapeutic Strategy for Neurodegenerative Diseases.International journal of molecular sciences · 2024Review
- Predicting therapeutic and side effects from drug binding affinities to human proteome structures.iScience · 2024Article
- Role of Serotonergic System in Regulating Brain Tumor-Associated Neuroinflammatory Responses.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Article
- Molecular Docking Assessment of Cathinones as 5-HTMolecules (Basel, Switzerland) · 2023Article
- On the construction of LIECE models for the serotonin receptor 5-HTJournal of computer-aided molecular design · 2023Article
- An Atomic Level Investigation of Sodium Ions Regulating Agonist and Antagonist Binding in the Active Site of a Novel Target 5HTCell biochemistry and biophysics · 2023Article
- Structure-Activity Relationship and Evaluation of Phenethylamine and Tryptamine Derivatives for Affinity towards 5-Hydroxytryptamine Type 2A Receptor.Biomolecules & therapeutics · 2023Article
- "Selective" serotonin 5-HTBiochemical pharmacology · 2022Review
- Impact of specific serotonin receptor modulation on restricted repetitive behaviors.Frontiers in behavioral neuroscience · 2022Review
- The roles of serotonin in cell adhesion and migration, and cytoskeletal remodeling.Cell adhesion & migration · 2021Review
- Evaluation of lorcaserin as an anticonvulsant in juvenile Fmr1 knockout mice.Epilepsy research · 2021Article
- Neuromodulation of Astrocytic KInternational journal of molecular sciences · 2021Article
- Lorcaserin Inhibit Glucose-Stimulated Insulin Secretion and Calcium Influx in Murine Pancreatic Islets.Frontiers in pharmacology · 2021Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1. Full length clones of the human 5-HT2B receptor were isolated from human liver, kidney and pancreas. The cloned human 5-HT2B receptors had a high degree of homology (approximately 80%) with the rat and mouse 5-HT2B receptors. 2. PCR amplification was used to determine the tissue distribution of human 5-HT2B receptor mRNA. mRNA encoding the 5-HT2B receptor was expressed with greatest abundance in human liver and kidney. Lower levels of expression were detected in cerebral cortex, whole brain, pancreas and spleen. Expression was not detected in heart. 3. Northern blot analysis confirmed the presence of 5-HT2B receptor mRNA (a 2.4 kB sized band) in pancreas, liver and kidney. An additional 3.2 kB sized band of hybridization was detected in liver and kidney. This raises the possibility of a splice variant of the receptor or the presence of an additional homologous receptor. 4. The human 5-HT2B receptor was expressed in Cos-7 cells and its ligand binding characteristics were compared to similarly expressed human 5-HT2A and 5-HT2C receptors. The ligand specificity of the human 5-HT2B receptor (5-HT > ritanserin > SB 204741 > spiperone) was distinct from that of the human 5-HT2A (ritanserin > spiperone > 5-HT > SB 204741) and 5-HT2C (ritanserin > 5-HT > spiperone = SB 204741) receptors. On the basis of a higher affinity for ketanserin and a lower affinity for yohimbine the human 5-HT2B receptor also appeared to differ from the rat 5-HT2B receptor. 5. These findings confirm the sequence of the human 5-HT2B receptor and they demonstrate that the receptor has a widespread tissue distribution. In addition, these data suggest that there are differences in ligand affinities between different species homologues of the receptor. Finally, the finding of two distinct bands on the Northern blots of liver and kidney raises the possibility of splice variants or subtypes of 5-HT2B receptors, within these tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.